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Abstract
Introduction We aimed to replicate association of newly
identified systemic lupus erythematosus (SLE) loci.
Methods We selected the most associated SNP in 10 SLE loci.
These 10 SNPs were analysed in 1,579 patients with SLE and
1,726 controls of European origin by single-base extension.
Comparison of allele frequencies between cases and controls
was done with the Mantel–Haenszel approach to account for
heterogeneity between sample collections.
Results A previously controversial association with a SNP in the
TYK2 gene was replicated (odds ratio (OR) = 0.79, P = 2.5 ×
10-5), as well as association with the X chromosome MECP2
gene (OR = 1.26, P = 0.00085 in women), which had only been
reported in a single study, and association with four other loci,
1q25.1  (OR = 0.81, P  = 0.0001), PXK  (OR = 1.19, P  =
0.0038), BANK1 (OR = 0.83, P = 0.006) and KIAA1542 (OR
= 0.84, P = 0.001), which have been identified in a genome-
wide association study, but not found in any other study. All
these replications showed the same disease-associated allele
as originally reported. No association was found with the LY9
SNP, which had been reported in a single study.
Conclusions Our results confirm nine SLE loci. For six of them,
TYK2,  MECP2,  1q25.1,  PXK,  BANK1  and  KIAA1542, this
BANK1: B-cell scaffold protein with ankyrin repeats 1; BLK: B-lymphoid tyrosine kinase; GWA: genome-wide association; IL: interleukin; ITGAM: 
integrin alpha M; LY9: lymphocyte antigen 9; MECP2: methyl CpG binding protein 2; OR: odds ratio; PXK: PX domain containing serine/threonine 
kinase; SLE: systemic lupus erythematosus; SLEGEN: International Consortium for Systemic Lupus Erythematosus Genetics; SNP: single nucleotide 
polymorphism; STAT4: signal transducer and activator of transcription; TYK2: tyrosine kinase 2.Arthritis Research & Therapy    Vol 11 No 3    Suarez-Gestal et al.
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replication is important. The other three loci, ITGAM, STAT4 and
C8orf13-BLK, were already clearly confirmed. Our results also
suggest that MECP2 association has no influence in the sex
bias of SLE, contrary to what has been proposed. In addition,
none of the other associations seems important in this respect.
Introduction
Systemic lupus erythematosus (SLE) is a complex autoim-
mune disease of wide variability in its manifestations and clini-
cal evolution that characteristically involves multiple
autoantibodies against ubiquitous nuclear antigens. Its
genetic component is very significant, as shown by a sibling
recurrence risk ratio of 20 and a 10-fold excess in SLE con-
cordance between monozygotic twins over dizygotic twins
[1,2].
Linkage studies have indicated that this genetic component is
due to multiple low-penetrance common genetic factors [1].
Only a few factors had consistently been demonstrated until
2008: the class II HLA alleles, low-affinity receptors for the
constant fraction of IgG, and the PTPN22 and IRF5 genes.
This scenario has been dramatically improved by new technol-
ogies and genome resources [2]. Four genome-wide associa-
tion (GWA) studies were published in 2008 [3-6] that,
together with other large-scale studies, have greatly enlarged
the number of convincing SLE-associated loci. Not all of the
newly described findings, however, have attained the same
degree of confirmation [2]. Some of them are already defini-
tively confirmed by replication in different sample collections
by the same authors and also by independent authors in sep-
arate studies (Table 1). In this group are the SLE associations
with the ITGAM [3,4,6,7], STAT4 [3,4,6,8-12] and C8orf13-
BLK regions [3,4,6]. Other findings are very solid but they still
require confirmation by independent studies. In this group are
the associated loci that were only reported in a single GWA
study but not in the other studies, such as BANK1 [5], PXK
[3], KIAA1542 [3] and 1q25.1 [3], or those that were reported
in a single large study but not in any of the four GWA studies,
such as MECP2 [13] and LY9 [14]. Finally, the TYK2 associ-
ation is more controversial because it was found in a large
study with Scandinavian families [15], partially replicated in a
large study of UK families [16], and excluded in one of the
GWA studies [3].
In the present paper, therefore, we have analysed SLE associ-
ation to each of these loci in more than 1,500 SLE patients
and 1,700 controls – and all of them except LY9 have been
clearly replicated. In addition, we have found that many of
these loci are also important for SLE in men where data from
previous reports is almost completely absent.
Materials and methods
Sample collection
We used DNA samples from SLE patients and ethnically
matched healthy controls of 16 collections from nine Euro-
pean countries (see Table S1 in Additional data file 1). Most of
these samples have already been described [17]. Two new
sample collections were from Asturias, Spain and Almada,
Portugal. Each recruiting centre was asked for about 100 SLE
patients and 100 ethnically matched controls. A total of 1,579
cases and 1,726 controls were obtained in this way. All SLE
patients met the revised American College of Rheumatology
classification criteria [18]. Clinical characteristics of the
patients are provided in Table S2 in Additional data file 1.
Patients and controls gave written informed consent. Sample
collection was approved by the respective ethical committees.
Genotyping
We selected a SNP for each of the 10 associated loci that we
intended to replicate (Table 1). The SNPs were selected
because they were strongly associated with SLE or because
they were described as probable causal polymorphisms.
These 10 SNPs were amplified in a single PCR with the Qia-
gen Multiplex PCR kit (Qiagen, Chatsworth, CA, USA) with 20
ng genomic DNA and 0.2 μM of each primer (for primers and
probes, see Table S3 in Additional data file 1). The PCR prod-
ucts were purified by digestion with Exonuclease I (Epicentre,
Madison, WI, USA) and shrimp alkaline phosphatase (GE
Healthcare, Barcelona, Spain). Purified PCR products were
genotyped by single-base extension with the SNaPshot Multi-
plex Kit (Applied Biosystems, Foster City, CA, USA) and spe-
cific probes. After a second purification with shrimp alkaline
phosphatase (GE Healthcare), samples were analysed in the
Abi Prism 3130xl Genetic Analyzer (Applied Biosystems) and
genotypes assigned by the GeneMapper software. All geno-
type calls were manually reviewed and conflicting results were
liberally re-assayed or re-genotyped by sequencing with the
Big Dye Ready Reaction Kit v 3.1 (Applied Biosystems).
Sequence reactions followed the kit manufacturer protocol
and were also analysed in the Abi Prism 3130xl Genetic Ana-
lyzer.
Statistical analysis
Some of the sample collections in our study have already been
used for the analysis of specific associations included in this
project. They have been excluded from the relevant analyses
to avoid data duplication; this circumstance is detailed in Table
S4 in Additional data file 1, where raw genotype data from
each sample collection are reported. Hardy-Weinberg equilib-
rium tests in control samples were performed with Haploview
with a threshold of 0.05 uncorrected for multiple tests [19].
Other statistical analyses were carried out in a customized ver-
sion of the Statistica 7.0 program (StatSoft, Tulsa, OK, USA).Available online http://arthritis-research.com/content/11/3/R69
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Comparison of cases and controls was carried out with the
Mantel–Haenszel approach because allele frequency differ-
ences are probable between sample collections even if spe-
cific effects on the phenotype are constant. Spurious false
positive or false negative results therefore become likely if the
allele differences are not accounted for. To avoid this, the Man-
tel–Haenszel approach combines effect sizes taken as the
odds ratio (OR) in each stratum allowing for heterogeneity in
allele frequencies. This approach provides an accurate com-
bined statistic if the heterogeneity of effect sizes, evaluated
with the Breslow–Day test, is excluded. Significant heteroge-
neity of effects is therefore excluded by the Breslow–Day test
and allele frequency heterogeneity is accounted for with the
Mantel–Haenszel approach. These analyses were also con-
ducted after stratifying the samples by gender. Univariate
logistic regression models were used to test the fit to the data
of additive, recessive and dominant genetic models. Statistical
power was estimated with the Power and sample size calcula-
tions software [20].
Table 1
Newly systemic lupus erythematosus-associated loci that were examined with previous evidence of association
Locus Chr. Location SNP Allelesa OR (95% CI) Associated Sample size Population Reference
ITGAM 16 Exon 3 rs1143679 G/A 1.78 (1.6 to 2.0) Yes 3,818 European American [7]
1.55 (1.2 to 2.0) Yes 1,289 African American [7]
2.07 (1.3 to 3.4) Yes 271 Gullah [7]
Other SNPs Yes [3,4,6]
STAT4 2 Intron 3 rs7574865 G/T 1.5 (1.2 to 1.8) Yes 3,057 European [3]
1.50 (1.4 to 1.7) Yes 4,651 European American [4]
1.55 (1.3 to 1.8) Yes 2,287 European American [8]
1.61 (1.4 to 1.9) Yes 2,495 Japanese [9]
1.62 (1.2 to 2.2) Yes 565 Colombians [10]
1.56 (1.4 to 1.7) Yes 3,958 European [12]
Other SNPs Yes [6,11]
C8orf13-BLK 8 Intergenic rs13277113 G/A 1.39 (1.3 to 1.5) Yes 6,301 European American [4]
Other SNPs Yes [3,6]
TYK2 19 Exon 8 rs2304256 C/A 0.625 (0.5 to 0.8) Yes 966 Swedish/Finnish [15]
105:127b No 380c European/Indo-
Pakistani
[16]
Other SNPs No [3]
MECP2 X Intron 2 rs17435 A/T 1.58 (1.3 to 1.9) Yes 1,364 Korean [13]
1.29 (1.1 to 1.5) Yes 2,160 European [13]
1q25.1 1 Intergenic rs10798269 G/A 0.82 (0.8 to 0.9) Yes 6,728 European [3]
BANK1 4 Intron 1 rs17266594 T/C 0.74 (0.6 to 0.9) Yes 927 Scandinavian [5]
0.70 (0.5 to 0.9) Yes 576 German [5]
0.63 (0.5 to 0.8) Yes 450 Italian [5]
0.78 (0.6 to 0.9) Yes 1,136 Spanish [5]
0.58 (0.4 to 0.8) Yes 620 Argentinian [5]
KIAA1542 11 Intron 4 rs4963128 G/A 0.78 (0.7 to 0.9) Yes 6,728 European [3]
PXK 3 Intron 5 rs6445975 T/G 1.25 (1.2 to 1.4) Yes 6,728 European [3]
LY9 1 Exon 8 rs509749 A/G 377:403d Yes 510c UK Caucasian [14]
237:251d No 270c Canadian [14]
Loci ordered as presented in Table 2. The SNPs selected for replication are detailed. Chr, chromosome; CI, confidence interval; OR, odds ratio. 
aMajor/minor alleles. bTransmitted:untransmitted. cNumber of families. dObserved:expected.Arthritis Research & Therapy    Vol 11 No 3    Suarez-Gestal et al.
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Results
A total of 1,579 SLE patients and 1,726 controls from 16
European collections were available for study (Tables S1 and
S2 in Additional data file 1). The genotyping call rate was
99.9% and the genotypes in controls were in Hardy-Weinberg
equilibrium. Individual collection data for each SNP is shown
in Tables S4 and S5 in Additional data file 1. Combined anal-
ysis of the SNP effects across our sample collections was per-
formed with the Mantel–Haenszel approach, which is a
method correcting for variability in allele frequencies between
collections provided that the effect sizes (that is, ORs) are not
significantly divergent. This condition was fulfilled because no
significant heterogeneity in OR was detected for any of the
SNPs (Table 2, final column).
The combined data showed significant differences between
SLE cases and controls for eight of the nine SNPs located in
autosomal chromosomes (Table 2). All of the significant differ-
ences between cases and controls were in the same direction
as originally reported (Tables 1 and 2). We found association
of the four SNPs that have been reported in a single GWA and
not yet replicated by independent studies: rs10798269 in
1q25.1 (OR = 0.81, P = 0.00013), rs6445975 in PXK (OR =
1.19, P = 0.0038), rs17266594 in BANK1 (OR = 0.83, P =
0.0062) and rs4963128 in KIAA1542  (OR = 0.84, P  =
0.0011). There was also significant association of two of the
three SNPs that were described in large studies but that were
not observed in any of the GWA studies: rs2304256 in TYK2
(OR = 0.79, P = 2.5 × 10-5) and rs17435 in MECP2 (analysis
of this SNP was performed separately in women and men
because this gene is in chromosome X; see below). Only
rs509749 in LY9 was similar in cases and controls. Our study
had sufficient power (80%) to detect association at this SNP
with an effect size equivalent to OR > 1.15 with P < 0.05 (or
OR > 1.23 for P < 0.001).
In addition to these important results for replication, we found
association with the three loci that have already been repli-
cated in GWA studies: rs1143679 in ITGAM (OR = 1.70, P
= 1.1 × 10-16), rs7574865 in STAT4 (OR = 1.62, P = 2.4 ×
10-12) and rs13277113 in C8orf13-BLK (OR = 1.34, P = 5.1
× 10-7). The effect sizes of these three association signals
(that is, their ORs) were larger than for all the other signals,
perhaps explaining the more consistent replication of their
association. Genotype comparisons for the different SNPs
were concordant with an additive genetic model and yielded
very similar results to the allele frequency analyses (data not
shown).
Combined analysis was also conducted in women (Table 3).
This was particularly necessary for the MECP2 SNP rs17435,
located in the X chromosome. This SNP showed a significant
difference between SLE women and control women and with
the same disease-associated allele as previously reported (OR
= 1.26, P = 0.00085). The SNPs placed in the autosomes
showed similar results to those obtained in the unstratified
analysis. There were only less significant P values due to the
smaller sample size, but the effect sizes (expressed as ORs)
remained largely unchanged. The BANK1 SNP was not asso-
ciated in women, but this was the SNP with fewer available
samples because we have excluded from this analysis the
sample collections that have previously been reported (power
was 0.68 for P = 0.05 and OR = 0.78, which was previously
reported in Spanish samples) [5].
No previous detailed information of men with SLE has been
published for any of these associated loci, although in a report
Table 2
Combined analysis of allele frequency differences between SLE cases and controls for nine autosomal loci
Minor allele frequency (%)a Mantel – Haenszel analysis Breslow – Day test
SNP (locus) SLE cases Controls OR (95% CI) P value P value
rs1143679 (ITGAM) 23.2 (730/3,152) 15.1 (521/3,448) 1.70 (1.5 to 1.9) 1.1 × 10-16 0.5
rs7574865 (STAT4) 32.8 (709/2,162) 23.2 (485/2,092) 1.62 (1.4 to 1.9) 2.4 × 10-12 1.0
rs13277113 (C8orf13-BLK) 30.9 (874/2,824) 25.7 (776/3,024) 1.34 (1.2 to 1.5) 5.1 × 10-7 1.0
rs2304256 (TYK2) 23.3 (733/3,152) 27.8 (960/3,450) 0.79 (0.7 to 0.9) 2.5 × 10-5 0.6
rs10798269 (1q25.1) 27.3 (861/3,158) 31.8 (1,098/3,452) 0.81 (0.7 to 0.9) 0.00013 0.2
rs17266594 (BANK1) 24 (526/2,192) 27.6 (624/2,260) 0.83 (0.7 to 0.9) 0.0062 0.4
rs4963128 (KIAA1542) 30.3 (955/3,150) 34.0 (1,173/3,448) 0.84 (0.8 to 0.9) 0.0011 0.2
rs6445975 (PXK) 27.3 (772/2,824) 24.2 (734/3,034) 1.19 (1.1 to 1.3) 0.0038 0.7
rs509749 (LY9) 43.1 (1,359/3,154) 43.8 (1,513/3,452) 0.97 (0.9 to 1.1) 0.5 0.4
Loci ordered by decreasing effect size (odds ratio (OR)). All results refer to the minor allele of each SNP, which is indicated in Table 1. CI, 
confidence interval; SLE, systemic lupus erythematosus. aData presented as percentage (number of minor alleles/total number of alleles).Available online http://arthritis-research.com/content/11/3/R69
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describing association of the ITGAM gene it was indicated
that results were not different between women and men [7].
This lack of information is probably due to the rarity of men suf-
fering from SLE. In our analysis, we have considered all male
data together without stratifying for sample collection due to
the low number of men in each collection (Table 4). Results in
men were similar to results in women, with the possible excep-
tion of the rs1143679 in ITGAM (OR = 2.08 versus 1.67; P =
0.03). Some SNPs were not associated in men (in the TYK2,
1q25.1, BANK1 and LY9 loci), but statistical power of this
subgroup analysis was low, ranging from 0.19 for
rs17266594 in BANK1  to 0.25 for rs2304256 in TYK2
among the nonassociated SNPs (power was estimated for P
= 0.05 and OR = 1.2).
Table 3
Combined analysis of allele frequency differences between SLE women and control women
Minor allele frequency (%)a Mantel – Haenszel analysis Breslow – Day test
SNP (locus) SLE cases Controls OR (95% CI) P value P value
rs1143679 (ITGAM) 22.3 (621/2,782) 15.1 (329/2,182) 1.67 (1.4 to 2.0) 2.0 × 10-11 0.6
rs7574865 (STAT4) 33.1 (636/1,920) 24.0 (317/1,322) 1.60 (1.4 to 1.9) 8.4 × 10-9 0.8
rs13277113 (C8orf13-BLK) 30.9 (777/2,514) 25.7 (475/1,848) 1.33 (1.2 to 1.5) 5.4 × 10-5 0.9
rs2304256 (TYK2) 22.9 (638/2,782) 27.2 (592/2,180) 0.81 (0.7 to 0.9) 0.0022 0.2
rs17435 (MECP2) 26.7 (744/2,784) 22.8 (498/2,186) 1.26 (1.1 to 1.4) 0.00085 0.7
rs10798269 (1q25.1) 27.1 (754/2,786) 32.3 (705/2,182) 0.77 (0.7 to 0.9) 6.2 × 10-5 0.4
rs17266594 (BANK1) 23.9 (464/1,938) 26.9 (386/1,436) 0.87 (0.7 to 1.0) 0.077 0.4
rs4963128 (KIAA1542) 30.4 (845/2,778) 33.9 (741/2,182) 0.85 (0.8 to 1.0) 0.011 0.2
rs6445975 (PXK) 26.7 (670/2,514) 23.5 (436/1,854) 1.22 (1.1 to 1.4) 0.0067 0.9
rs509749 (LY9) 43.3 (1,206/2,784) 44.0 (962/2,184) 0.98 (0.9 to 1.1) 0.7 0.5
Loci ordered as presented in Table 2. All results refer to the minor allele of each SNP, which is indicated in Table 1. CI, confidence interval; OR, 
odds ratio; SLE, systemic lupus erythematosus. aData presented as percentage (number of minor alleles/total number of alleles).
Table 4
Comparison of SNP allele frequencies between SLE men and control men
Minor allele frequency (%)a Mantel – Haenszel analysis
SNP (locus) SLE cases Controls OR (95% CI) P value
rs1143679 (ITGAM) 27.9 (83/298) 15.7 (181/1,154) 2.08 (1.5 to 2.8) 1.2 × 10-6
rs7574865 (STAT4) 31.7 (64/202) 21.5 (159/740) 1.69 (1.2 to 2.4) 0.0025
rs13277113 (C8orf13-BLK) 31.0 (88/284) 25.1 (267/1,064) 1.34 (1.0 to 1.8) 0.045
rs2304256 (TYK2) 26.8 (80/298) 28.8 (334/1,158) 0.91 (0.7 to 1.2) 0.5
rs17435 (MECP2)b 29.2 (42/144) 18.5 (105/568) 1.82 (1.2 to 2.8) 0.0046
rs10798269 (1q25.1) 28.0 (84/300) 30.7 (355/1,158) 0.88 (0.7 to 1.2) 0.4
rs17266594 (BANK1) 26.2 (56/214) 28.4 (227/798) 0.89 (0.6 to 1.3) 0.5
rs4963128 (KIAA1542) 28.0 (84/300) 34.9 (403/1,156) 0.73 (0.6 to 1.0) 0.025
rs6445975 (PXK) 32.1 (86/268) 24.8 (265/1,068) 1.43 (1.1 to 1.9) 0.016
rs509749 (LY9) 40.6 (121/298) 42.9 (496/1,156) 0.91 (0.7 to 1.2) 0.5
Loci ordered as presented in Table 2. All results refer to the minor allele of each SNP, which is indicated in Table 1. No stratified analysis by 
sample collection was done due to the small number of patients with systemic lupus erythematosus (SLE) in each collection. CI, confidence 
interval; OR, odds ratio. aData presented as percentage (number of minor alleles/total number of alleles). bThese results are of carrier analysis 
because MECP2 is in the X chromosome and there is a single allele in each man.Arthritis Research & Therapy    Vol 11 No 3    Suarez-Gestal et al.
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Discussion
Our aim has been to contribute to the definition of consistent
SLE genetic factors derived from recent sound studies: four of
the associations have been described in a GWA study, but not
in a second GWA study or any other study; another two asso-
ciations were identified in large studies, but not in any of the
GWA studies; and one association is more controversial
(Table 1). Our results are highly reassuring because all of the
associations, except one from the group not found in any
GWA study, were replicated with clarity and showed the same
disease-associated allele as originally reported. This high
degree of reproducibility is a fundamental change that large
studies have brought to genetic research of SLE and other
complex diseases [2,21]. This change allows a bright future
for the investigation of the genetic component of SLE.
The most remarkable result from the present study has proba-
bly been the association signal observed with the rs2304256
nonsynonymous SNP of TYK2 (OR = 0.79) because this has
been a controversial SLE genetic factor. The rs2304256 SNP
introduces a valine to phenylalanine change in the Janus
homology domain 4 of TYK2 whose functional relevance has
not yet been tested. This nonsynonymous SNP showed the
strongest association among the 11 TYK2 SNPs studied in
Scandinavian families [15], but was not associated in a study
of UK families [16]. This latter study, however, found associa-
tion with another TYK2 SNP (rs12720270) that was not asso-
ciated in the Scandinavian study. Finally, the International
Consortium for Systemic Lupus Erythematosus Genetics
(SLEGEN) GWA study excluded association with the
rs12720270 SNP (the rs2304256 SNP was not included in
the GWA panels) [3]. Our results are important in this context
because they show a significant association that confirms the
role of the rs2304256 nonsynonymous SNP. In addition, com-
bined analysis of all available data show a clear SLE associa-
tion (P = 2.10 × 10-11) that is stronger than the required for
genome-wide significance.
Tyk2 is a Janus-family tyrosine kinase that is bound to cytokine
receptors and becomes activated after ligand binding. Defi-
ciency of TYK2 leads to defects of multiple cytokine pathways,
including type I interferon, IL-6, IL-10, IL-12, and IL-23, and to
impaired T-helper type 1 differentiation and accelerated T-
helper type 2 differentiation [22]. Only future research will indi-
cate which of these pathways is critically affected by the TYK2
risk allele.
Following in importance is the association of MECP2 because
our results provide replication and indicate that a previous
assumption about the role of this genetic factor in contributing
to the sex bias in SLE is questionable. Sawalha and col-
leagues considered the X-chromosome methyl CpG binding
protein 2 coding gene (MECP2) as a possible SLE genetic
factor based on two features: SLE predominance in women
and abnormal regulation of methylation-sensitive T-cell genes
in SLE [13]. MECP2 could be involved in both phenomena
because this gene is in the X chromosome and participates in
DNA methylation. Sawalha and colleagues found association
with several SNPs in women from two ethnic groups, Korean
and European (OR for rs17435 = 1.58 and 1.29, respectively)
[13]. The association we have found in women (OR = 1.26) is
very similar to that reported in their European sample, provid-
ing strong confirmatory evidence. This replication is important
for the status of MECP2 due to the lack of association signals
in the SLE GWA studies.
In addition, we have found that the MECP2 SNP is also asso-
ciated with SLE in men (OR = 1.82, P = 0.0046), which was
not previously known. This result seriously undermines the
hypothesized role of MECP2 in SLE gender bias. In retro-
spect, lack of sex specificity is congruent with experiments
that showed MECP2 is not expressed in the inactivated X
chromosome of women [23], which implies expression levels
in men and women should be equivalent. Future research
should aim to establish whether any of the SLE-associated
SNPs in MECP2 has a functional effect and to find evidence
of the hypothesized relationship between altered methylation
of T-cell genes in SLE and MECP2. In addition, it is even
unclear whether the causal polymorphism affects MECP2
because SLE association has also been reported with genetic
variants in a neighbour gene, IRAK1, which is a key mediator
in the signalling pathways of Toll-like receptors/IL-1R [24].
The rs10798269 SNP in the 1q25.1 locus, the rs4963128
SNP in the KIAA1542 gene and the rs6445975 SNP in the
PXK gene were reported in the SLEGEN GWA study [3] with
P values below 2 × 10-7, but they were not reported in Hom
and colleagues' GWA study [4] and none of them has yet
been replicated in any other study. The three SNPs were asso-
ciated with SLE in our study, with effect sizes that are similar
to those reported (OR = 0.81 versus 0.82 for the 1q25.1
SNP, 0.84 versus 0.78 for the KIAA1542 SNP, and 1.19 ver-
sus 1.25 for the PXK SNP). None of these three SNPs has any
predictable functional effect. In addition, the rs10798269
SNP in the 1q25.1 locus is far from any known transcript and
the PXK and KIAA1542 genes are of unknown function. The
KIAA1542 gene, however, is about 20 kb away from the IRF7
gene and in linkage disequilibrium with it, raising the possibility
that this association could be related with IRF7 function [3].
Our replication of these associations increases the need for
research aimed to the identification of their functional effects.
We have also found a significant association with the
rs17266594 in the BANK1 gene. This SLE genetic factor has
been identified in a low-resolution GWA study in a Swedish
sample and replicated in other European sample collections in
the same study [5], but it was not found in any of the high-res-
olution GWA studies and has not yet been replicated by other
groups. Our results provide this independent replication,
although with a more modest effect (OR = 0.83 in our studyAvailable online http://arthritis-research.com/content/11/3/R69
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versus 0.70 in Kozyrev and colleagues [5]). The causal poly-
morphism can be the rs17266594 SNP itself, which seems to
alter splicing efficiency of BANK1, or two BANK1 nonsynon-
ymous SNPs of possible damaging effect. Linkage disequilib-
rium between these three SNPs has prevented dissection of
their relationship to SLE susceptibility [5]. BANK1 codes for a
B-cell scaffold protein with ankyrin repeats that is implicated in
B-cell receptor-mediated signalling.
The rs509749 SNP of LY9 is the only SNP that was not repli-
cated in our study. We selected this SNP because it seems to
explain the 1q23 SLE-linked locus according to a large family-
based study [14]. 1q23 is one of the most consistently
described SLE loci in linkage studies (and its syntenic region
in the mouse lupus models) [1]. Examination of SNPs all along
this locus showed stronger association with the rs509749
SNP [14]. This SNP has a predictable impact in protein func-
tion and is associated with changes in the proportion of spe-
cific T-cell subsets [14]. All this evidence made the rs509749
SNP a good candidate for replication in our view, even if the
level of significance of the SLE association was notably lower
than the reported for the other nine SNPs studied here (P =
0.002). Lack of replication of this SNP in contrast with replica-
tion of the other nine SNPs provides support for the direct rela-
tionship between very low P values obtained in sound studies
and the reproducibility of genetic association findings [21].
The most associated SNPs in our samples were the three that
were already confirmed previous to our study. These three
SNPs were associated with SLE in at least three large studies.
The largest effect was observed with a nonsynonymous SNP
in the third exon of the ITGAM gene (rs1143679, OR = 1.70)
[3,4,6,7]. This nonsynonymous SNP was the most associated
in one of the previous studies (with very similar effect, OR =
1.74) [7], and has been hypothesized to disturb ITGAM inter-
action with its ligands, but still no functional evidence is avail-
able. Another clearly established association [3,4,6,8-12] was
the second strongest in our study: SNP rs7574865 in the
third intron of the STAT4 gene (OR = 1.62). This association
seems stronger in patients with a severe phenotype [12]; how-
ever, no functional polymorphism has been identified in this
locus. The next strongest association (OR = 1.34) was with
the rs13277113 SNP, which has been reported in the GWA
study of Hom and colleagues [4], with a similar effect (OR =
1.39). This SNP is located between C8orf13 (of unknown
function) and BLK (B-lymphoid tyrosine kinase), two genes
that are transcribed in opposite directions. No functional vari-
ant has been identified in this locus, but the risk allele of this
SNP correlates with low mRNA levels of BLK and high levels
of  C8orf13, raising the possibility that either of these two
effects could be related with SLE. Graham and colleagues
found association with a strongly linked SNP in the BLK gene
[6], while the SLEGEN GWA study found association with an
unlinked SNP in this locus, suggesting the possibility of two
independent genetic factors [3].
In addition, we have found that most examined SLE-associ-
ated SNPs seem to be shared between women and men.
Results are not definitive given the small number of men in the
patient group. This lack of differential association is important
because we do not know definitively the causes of the female
preference of SLE. Lack of detailed gender analysis in previ-
ous genetic reports is regrettable because only aggregation of
data from multiple studies will allow us to know whether
genetic factors contribute to this sex bias.
Conclusions
In summary, our study has provided independent replication of
nine SLE-associated loci, six of them of confirmatory impor-
tance because they have not yet been independently repli-
cated by other groups (1q25.1, MECP2, KIAA1542, PXK and
BANK1) or because their association was controversial
(TYK2). These results bring the number of strongly confirmed
associated loci to 13. Replication in independent studies is
indispensable for considering a genetic factor in this category,
although the common use of multiple case–control sets inside
the same study or of large sample collections has increased
the chances of replication [2]. Some other promising associa-
tions have been discovered [6,25], or await sufficient inde-
pendent replication [2], but it is already certain that the genetic
component of SLE is especially rich in genetic factors with
effects above the detectable level with current studies (OR =
1.15 to 1.25). We are therefore now in a phase of exciting dis-
coveries in this field. There still remain formidable challenges,
however, because it is necessary to transform the information
we obtain into useful knowledge and, as has been discussed
above, we have very few clues regarding the meaning of the
identified SLE associations. Future studies should try to iden-
tify the causal variants and to determine their effect at molec-
ular, cellular and disease levels, including the assessment of
their role in the different SLE phenotypes and the probable
similar effect in women and men.
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